- Motley Fool
Down 57%, Is AbCellera Biologics a Buy on the Dip?
Wall Street analysts say this drug developer can more than double your money.
- InvestorPlace
3 Stock Gems Hiding in the Nasdaq
With the technology benchmark Nasdaq index encountering some choppy weather since April, speculators may want to consider undervalued Nasdaq stocks. Granted, it’s always risky betting on enterprises that haven’t caught other people’s attention. Still, the rewards could be fantastic. It’s just like going to the discount rack at your favorite luxury department store. You might find apparel that’s marked 50% off. However, a quick look at the sizes and you’ll quickly discover why the retailer is so
- Insider Monkey
AbCellera Biologics Inc. (NASDAQ:ABCL) Q1 2024 Earnings Call Transcript
AbCellera Biologics Inc. (NASDAQ:ABCL) Q1 2024 Earnings Call Transcript May 7, 2024 AbCellera Biologics Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good afternoon and welcome to AbCellera’s Q1, 2024 Business Update Conference Call. My name is Harry and […]
